Natco Pharma | Business Upturn

Natco Pharma shares surge over 3% after board approves demerger of agrochemicals business

Aman Shukla — Wed, 25 Mar 2026 03:52:03 +0000

Natco Pharma shares gained over 3% in early trade on March 25 after the company announced a key corporate restructuring plan along with other strategic decisions.

The company informed exchanges that its board has approved a scheme of arrangement involving the demerger of its agrochemicals business into a separate entity, Natco Crop Health Sciences Limited. The move is aimed at segregating its pharmaceutical and agrochemical verticals to enable focused growth and operational efficiency.

As per the approved scheme, the agrochemicals business will be transferred to the resulting company on a going concern basis. Shareholders of Natco Pharma will receive one equity share of the resulting company for every one share held in the parent company.

The agrochemicals division contributed around ₹60.62 crore in turnover for FY25, accounting for approximately 1.48% of the company’s total revenue. Despite its relatively small contribution, the company believes the segment has distinct risk-reward dynamics compared to its core pharmaceutical business.

The demerger is expected to allow both verticals to operate independently with better capital allocation, sharper management focus, and improved operational efficiency. The company also noted that the restructuring could help unlock value for shareholders over the long term.

In addition to the demerger, Natco Pharma’s board approved the incorporation of a wholly owned subsidiary in Nigeria with an investment of up to $100,000. The company also plans to liquidate its Australian subsidiary due to lack of economic viability under the current business model.

The proposed scheme remains subject to approvals from shareholders, creditors, stock exchanges, and the National Company Law Tribunal (NCLT).

Eris Lifesciences partners with Natco Pharma for semaglutide launch in India

Yash Agarwal — Fri, 20 Mar 2026 10:38:52 +0000

Eris Lifesciences Limited has announced a strategic partnership with Natco Pharma Limited to commercialise Semaglutide in India. This move aims to bolster Eris’s leadership in the rapidly expanding diabetes and metabolic care market.

Semaglutide, a GLP-1 receptor agonist, is recognised globally for its effectiveness in managing Type 2 diabetes and chronic weight issues. The drug’s introduction is timely, as India faces a growing diabetic population and increasing awareness of obesity management. GLP-1 therapies, such as Semaglutide, present significant growth opportunities in the metabolic segment.

Eris Lifesciences has established a robust presence in the diabetology field, engaging extensively with specialists across India. The addition of Semaglutide is anticipated to enhance Eris’s portfolio in advanced diabetes therapies and expand its role in next-generation metabolic treatments.

The partnership leverages the strengths of both companies: Eris’s strong commercial presence and diabetes franchise, and Natco’s expertise in manufacturing and regulatory processes for complex formulations.

Strategic Partnership Details

Natco Pharma has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic Semaglutide for the Indian market. The launch is expected in March 2026, targeting Type 2 diabetes management and addressing unmet needs in India’s metabolic care landscape.

Leadership Commentary

Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, stated, “Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well positioned to drive rapid adoption and enhance patient access in India.”

Bakshi further noted that Eris has been preparing its commercial strategy to capitalise on the GLP-1 opportunity, viewing this partnership as a long-term value driver for the company.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Natco Pharma launches Semaglutide generic injection in India at Rs 1,290

Yash Agarwal — Fri, 20 Mar 2026 04:01:19 +0000

Natco Pharma Limited has announced the launch of its generic Semaglutide injection in India, available from March 21, 2026. The product, offered in multi-dose vials, is priced at a starting MRP of ₹1,290, making it the most affordable option in the market.

The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the generic version of Semaglutide. This medication is indicated for adults with type 2 diabetes mellitus who have not achieved sufficient control through diet and exercise alone.

Natco’s Semaglutide injection will be available in vial strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANAT and SEMAFULL. The vials are priced at ₹1,290 per month for the 2mg/1.5ml and 4mg/3ml strengths, and ₹1,750 for the 8mg/3ml strength.

In addition to vials, Natco plans to launch a pen device version in April 2026, with prices set at ₹4,000, ₹4,200, and ₹4,500 per month for the respective strengths. The company is the first to offer Semaglutide in a vial dosage form, which is approximately 70% cheaper than the pen device and 90% cheaper than the innovator’s brand.

Natco’s introduction of this cost-effective GLP-1 therapy aims to enhance patient accessibility and support long-term compliance for those requiring diabetes management.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Natco Pharma to consider agri business demerger on March 24

Markets Desk — Wed, 18 Mar 2026 10:55:52 +0000

Natco Pharma Limited has informed exchanges that its board of directors will meet on March 24, 2026, to consider a proposal for the demerger of its agri business. The company, in a post-market filing dated March 18, said it will evaluate a scheme of arrangement to spin off its Agrosciences Division into its wholly owned subsidiary, Natco Crop Health Sciences Limited, on a going concern basis.

The proposed restructuring is aimed at segregating the agrochemicals business into a separate entity, allowing focused operations and strategic clarity for both segments. The move could potentially help in improving operational efficiencies and enabling better value discovery over the longer term.

The company also stated that the trading window for dealing in its securities will remain closed from March 19 to March 26, 2026 (both days inclusive), in line with SEBI’s insider trading regulations, and will reopen on March 27, 2026.

Since the disclosure was made after market hours, the stock did not react to the development during the trading session. Shares of Natco Pharma ended at ₹957.90 on March 18, up 1.59% for the day.

Natco Pharma shares rise over 2% after launch of generic Pomalidomide Capsules in the US

Aman Shukla — Wed, 04 Mar 2026 03:51:16 +0000

Shares of Natco Pharma moved higher in early trade on Wednesday after the pharmaceutical company announced the launch of Pomalidomide Capsules in the United States in partnership with Breckenridge Pharmaceutical, Inc.. The product is a generic version of Pomalyst, originally marketed by Celgene.

The stock rallied more than 2% following the announcement as investors reacted to the company’s entry into a high-value oncology drug segment in the US market.

Natco Pharma said that Pomalidomide Capsules are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression on or within 60 days of completing their last treatment.

The drug is also approved for the treatment of AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients diagnosed with Kaposi sarcoma.

The capsules will be available in four strengths — 1mg, 2mg, 3mg, and 4mg — and will primarily be distributed through specialty pharmacies and clinics across the United States. Pomalidomide is a thalidomide analogue widely used in the treatment of advanced-stage multiple myeloma.

According to industry sales estimates, Pomalidomide Capsules recorded US sales of around USD 3.2 billion for the 12-month period ending September 2025, highlighting the large market opportunity for generic manufacturers entering the segment.

Natco Pharma launches Generic Pomalidomide Capsules in US market

Aman Shukla — Tue, 03 Mar 2026 05:08:59 +0000

Natco Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has announced the launch of Pomalidomide Capsules in the United States in partnership with Breckenridge Pharmaceutical, Inc.. The product is a generic version of Pomalyst, originally marketed by Celgene.

Pomalidomide Capsules are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug is also approved for the treatment of AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.

The capsules are available in 1mg, 2mg, 3mg, and 4mg strengths and will be distributed primarily through specialty pharmacies and clinics across the US. Pomalidomide is a thalidomide analogue widely used in advanced-stage multiple myeloma treatment.

According to industry sales data, Pomalidomide Capsules in the US recorded estimated sales of USD 3.2 billion for the 12-month period ending September 2025. The significant market size underscores the commercial opportunity for generic manufacturers entering this segment.

Natco Pharma stated that, based on information made available by the US Food and Drug Administration, it believes it has secured 180 days of shared exclusivity for the product in the US market. This exclusivity period could provide a competitive advantage during the initial phase of commercialization.

Why are NATCO Pharma shares up over 9% today: Explained

Aman Shukla — Mon, 16 Feb 2026 04:14:10 +0000

Shares of NATCO Pharma Limited rallied more than 9% after the company received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India. The company confirmed that the product will be launched in the domestic market in March 2026.

The approval marks NATCO’s entry into one of the fastest-growing segments of diabetes treatment. Semaglutide, a GLP-1 receptor agonist, is prescribed for adults with insufficiently controlled Type 2 diabetes mellitus and is used alongside diet and exercise to improve blood sugar management. With India witnessing a steady rise in diabetes cases, the availability of a generic version is expected to expand patient access to advanced therapies at a potentially more affordable price point.

The development is seen as strategically important for NATCO as GLP-1-based treatments continue to gain traction globally. By adding Semaglutide to its domestic portfolio, the company strengthens its presence in the chronic therapy segment while leveraging its manufacturing and regulatory capabilities.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

NATCO Pharma gets CDSCO approval for Generic Semaglutide Injection, launch set for March 2026

Aman Shukla — Sat, 14 Feb 2026 04:37:33 +0000

NATCO Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India. The company has announced that the product will be launched in the domestic market in March 2026, marking its entry into one of the fastest-growing segments in diabetes treatment.

Semaglutide is indicated for the treatment of adults with insufficiently controlled Type 2 diabetes mellitus and is prescribed as an adjunct to diet and exercise. With diabetes cases continuing to rise across India, the approval is expected to improve accessibility to advanced GLP-1-based therapies at a potentially more affordable cost.

Headquartered in Hyderabad, NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty medicines, active pharmaceutical ingredients and crop protection products. The company is known for its strong research-driven approach and has established itself as a leading oncology player in the domestic targeted therapies market. It also focuses on limited-competition molecules in the United States, strengthening its presence in regulated markets.

NATCO operates nine manufacturing facilities and two R&D centers in India. Its plants are approved by leading regulatory authorities including the U.S. FDA, Brazil’s ANVISA, Health Canada and the WHO. The company supplies products to more than 50 global markets, underlining its strong international footprint.

Natco Pharma receives USFDA EIR for Chennai API unit; Inspection classified as VAI

Aman Shukla — Fri, 13 Feb 2026 03:57:14 +0000

Natco Pharma Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility located in Manali, Chennai. The inspection has been classified as Voluntary Action Indicated (VAI), according to a regulatory filing made by the company.

The USFDA conducted an inspection at the Chennai-based API division from November 17 to November 21, 2025. Following the inspection, the company had received seven observations in Form 483. With the issuance of the EIR and classification as VAI, the inspection process has now been formally closed by the US regulator.

A VAI classification indicates that while certain observations were noted during the inspection, the agency does not intend to take or recommend regulatory enforcement action at this stage. The company is expected to address the observations through appropriate corrective and preventive actions.

Headquartered in Hyderabad, Natco Pharma develops, manufactures and markets generic and branded pharmaceuticals, specialty medicines, active pharmaceutical ingredients and crop protection products. The company is known for its focus on oncology and targeted therapies in the domestic market and limited-competition molecules in the United States.

Natco Pharma operates nine manufacturing facilities and two research and development centres in India. Its manufacturing sites are approved by multiple global regulatory authorities, including the USFDA, Brazil’s ANVISA, Health Canada and the World Health Organization, and the company serves more than 50 international markets.

Natco Pharma Q3 Results: Revenue jumps 36.3% YoY to Rs 647.3 crore, net profit up 14.3%

Aman Shukla — Thu, 12 Feb 2026 09:11:55 +0000

Natco Pharma reported a mixed set of numbers for the third quarter ended December 31, 2025, with strong revenue growth but some pressure on margins on a year-on-year basis.

Revenue from operations surged 36.3% YoY to ₹647.3 crore in Q3FY26, compared with ₹474.8 crore in the corresponding quarter last year. However, other income declined sharply by 67.1% YoY to ₹58.1 crore from ₹176.3 crore a year ago. As a result, total income increased 8.3% YoY to ₹705.4 crore, up from ₹651.1 crore in Q3FY25.

On the expenditure side, total expenses rose 11.7% YoY to ₹544.3 crore, compared with ₹487.4 crore in the year-ago period. The rise in expenses outpaced the growth in total income, leading to a marginal decline in profitability at the operating level.

Profit before tax slipped 1.6% YoY to ₹161.1 crore from ₹163.7 crore in Q3FY25. Total tax expense declined 33.9% YoY to ₹20.7 crore versus ₹31.3 crore last year, providing some cushion to the bottom line.

Profit before share of profit from associate stood at ₹140.4 crore, up 6.0% YoY from ₹132.4 crore. After accounting for share of profit from associate of ₹10.9 crore during the quarter, net profit rose 14.3% YoY to ₹151.3 crore, compared with ₹132.4 crore in the corresponding quarter of the previous financial year.

NATCO Pharma concludes US FDA inspection at Chennai API unit, receives seven form 483 observations

Aman Shukla — Fri, 21 Nov 2025 10:48:04 +0000

NATCO Pharma Limited has confirmed the successful completion of a US FDA inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility in Manali, Chennai. The inspection was carried out from November 17 to November 21, 2025, covering the company’s quality systems, processes, and compliance standards.

At the end of the review, the company received seven observations under Form 483. NATCO mentioned that these findings are procedural in nature and not related to product quality. The management also stated that they are confident about addressing all observations with a comprehensive response.

NATCO reiterated that it remains fully committed to maintaining cGMP compliance and continuing to supply safe, high-quality pharmaceutical products to customers and patients around the world.

NATCO Pharma Q2 Results: Net profit drops 23% YoY to Rs 518 crore, revenue flat at Rs 1,363 crore

Aman Shukla — Fri, 14 Nov 2025 08:05:52 +0000

NATCO Pharma reported a steady performance in its Q2 FY26 numbers, with a mix of moderate revenue growth and softer profitability when compared to the same period last year. The company’s consolidated revenue from operations for the quarter stood at ₹1,363 crore, slightly lower than ₹1,371 crore recorded in Q2 FY25, marking a 0.6% decline year-on-year.

Including other income, the total income for the quarter came in at ₹1,463 crore, almost flat when compared with ₹1,435 crore last year, reflecting a 2% YoY increase supported largely by higher other income.

On the expense front, total expenses rose to ₹849 crore, compared with ₹617 crore in the corresponding quarter last year. This represents a significant increase of about 37.5% YoY, driven mainly by higher employee costs, depreciation, and a notable jump in other expenses.

EBITDA for the quarter came in at ₹579 crore, down from ₹804 crore in the previous year, marking a 28% YoY decline. Operating margins also compressed notably, dropping to 42.5% compared with 58.6% last year, reflecting the impact of higher costs across multiple fronts.

Profit before tax for the quarter came in at ₹614 crore, a decline from ₹818 crore last year, translating to a 24.9% YoY drop. Finally, the bottom line for Q2 FY26 stood at ₹518 crore, compared with ₹677 crore in Q2 FY25, reflecting a 23.5% year-on-year decline in net profit.

NATCO Pharma launches Generic Everolimus Tablets 1mg in the U.S. market

Aman Shukla — Fri, 31 Oct 2025 03:42:54 +0000

NATCO Pharma Limited has announced the launch of Everolimus Tablets 1mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressants. The launch marks another milestone in NATCO’s ongoing efforts to strengthen its global presence in niche pharmaceutical segments.

The product will be marketed in the U.S. by Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, which plans to roll out the Everolimus 1mg tablets immediately. Everolimus acts as an mTOR inhibitor immunosuppressant, primarily used for the prophylaxis of organ rejection in adult kidney and liver transplant patients.

Breckenridge had earlier launched Everolimus tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blister packs introduced in July 2021 and bottle formulations made available in June 2023. The addition of the 1mg variant now completes the product range, enhancing treatment flexibility for physicians and patients.

About NATCO Pharma Limited

Headquartered in Hyderabad, NATCO Pharma Limited is a research-driven pharmaceutical company known for developing, manufacturing, and marketing both generic and specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and crop protection products. The company is a major player in oncology and targeted therapies in India and focuses on limited-competition molecules in the U.S. market.

NATCO operates nine manufacturing sites and two R&D facilities across India, all of which meet international regulatory standards. Its facilities are approved by top global health authorities, including the U.S. FDA, Brazil ANVISA, Health Canada, and WHO, enabling the company to cater to over 50 global markets.

The launch of Everolimus Tablets 1mg further reinforces NATCO’s commitment to delivering affordable and high-quality healthcare solutions worldwide while expanding its footprint in the U.S. generic drug market.

Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity

Aman Shukla — Wed, 20 Aug 2025 05:25:20 +0000

NATCO Pharma Limited has announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg in the United States, a generic version of Tracleer® developed by Actelion Pharmaceuticals US Inc. The product will be marketed in partnership with Lupin Limited.

NATCO holds the first-to-file status, securing 180 days of generic drug exclusivity for this launch. Bosentan TFOS is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged three years and older suffering from idiopathic or congenital PAH. The drug helps reduce pulmonary vascular resistance (PVR), which is expected to enhance exercise capacity in affected patients.

According to industry sales data, Bosentan tablets for oral suspension (32mg) recorded an estimated USD 10 million in U.S. sales for the 12 months ending June 2025.

The launch strengthens NATCO’s presence in the U.S. generics market and reinforces its strategy of focusing on niche, high-value products.

Natco Pharma board declares interim dividend of Rs 2 per share for FY26

Aman Shukla — Tue, 12 Aug 2025 08:24:07 +0000

Natco Pharma has declared an interim dividend of ₹2 per equity share (face value ₹2 each), translating to a 100% payout for the financial year 2025-26.

The company has set Tuesday, August 19, 2025, as the record date to determine the list of shareholders eligible for the dividend. Those holding shares of Natco Pharma on this date will be entitled to receive the payout.

As per the company’s announcement, the distribution of the interim dividend will commence from August 26, 2025. This move underscores Natco Pharma’s consistent commitment to rewarding its investors while maintaining strong financial performance.

NATCO Pharma Q1 Results

NATCO Pharma has announced its financial results for the first quarter ended June 30, 2025, showing largely stable revenue but a sharp drop in profitability compared to last year.

The company posted a consolidated total revenue of ₹1,390.6 crore in Q1 FY26, a marginal 1.42% decline from ₹1,410.7 crore in the same quarter of the previous fiscal. Despite the flat revenue trend, operating performance remained strong, with EBITDA coming in at ₹632.7 crore, translating to robust margins of 45.5%.

However, profitability took a significant hit. Consolidated net profit fell to ₹480.3 crore, down 28.1% from ₹668 crore in Q1 FY25.

NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY

Aman Shukla — Tue, 12 Aug 2025 08:03:32 +0000

NATCO Pharma has posted its financial results for the first quarter ended June 30, 2025, reporting a consolidated total revenue of ₹1,390.6 crore, down slightly from ₹1,410.7 crore in the same period last year. The company recorded an EBITDA of ₹632.7 crore, translating to strong margins of 45.5%. Consolidated net profit for the quarter stood at ₹480.3 crore, marking a 28.1% decline from ₹668 crore in Q1 FY25.

The quarter was marked by pricing pressure in the US product portfolio and higher R&D expenses, with the company investing in high-value projects to strengthen its pipeline. Despite these challenges, NATCO Pharma’s Board of Directors has announced an interim dividend of ₹2 per equity share of face value ₹2 each for Q1 FY26.

Segment-wise Performance

Active Pharmaceutical Ingredients (API): ₹52.6 crore in Q1 FY26, up from ₹39.2 crore in Q1 FY25.
Domestic Formulations: ₹107 crore, compared to ₹102.2 crore last year.
Formulations Export (Including profit share and subsidiaries): ₹1,126.5 crore, down from ₹1,210.1 crore in the year-ago quarter.
Crop Health Sciences (CHS): ₹34.7 crore, more than double last year’s ₹15.6 crore.
Other Income: ₹69.8 crore, higher than ₹43.6 crore in Q1 FY25.

Sequentially, the company’s total revenue rose from ₹1,287.3 crore in Q4 FY25 to ₹1,390.6 crore in Q1 FY26, reflecting growth across most business segments except exports, which saw a YoY decline.

Natco Pharma gets EIR from USFDA for Hyderabad API facility

Aman Shukla — Thu, 24 Jul 2025 08:35:15 +0000

NATCO Pharma Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Active Pharmaceutical Ingredient (API) facility located in Mekaguda, Hyderabad. This follows a recent inspection that was carried out between June 9 and June 13, 2025.

During the inspection, the FDA issued one observation under Form 483, which was classified as “Voluntary Action Indicated” (VAI). This classification implies that the issues noted are not serious enough to warrant any regulatory or enforcement action, and NATCO can voluntarily correct them. With the EIR now issued on July 24, 2025, it signals the closure of the inspection process, which is generally a positive outcome for the company.

NATCO Pharma, based in Hyderabad, is known for its focus on research-driven, specialty and generic pharmaceuticals, including strong capabilities in oncology and targeted therapies in the domestic market. The company also has a strong presence in the U.S. market, particularly in limited-competition molecules.

In addition to pharmaceuticals, NATCO is active in crop protection products. The company operates nine manufacturing facilities and two R&D centers across India, with approvals from major global regulators such as the US FDA, Health Canada, ANVISA (Brazil), and the WHO. NATCO currently serves over 50 international markets.

Natco Pharma offers to acquire 35.75% stake in South Africa’s Adcock Ingram for Rs 2,000 crore

Aman Shukla — Wed, 23 Jul 2025 10:39:09 +0000

NATCO Pharma is making a bold move into the South African pharmaceutical market. The company’s board has approved a major strategic investment to acquire a 35.75% stake in Adcock Ingram Holdings Limited, a leading pharmaceutical company based in South Africa. This includes NATCO’s earlier holding of 0.80%.

The acquisition, valued at around ₹2,000 crore (approximately ZAR 4 billion), involves buying over 5 crore shares from public shareholders and Adcock’s treasury. NATCO has offered ZAR 75 (around USD 4.27) per share in an all-cash deal. If accepted, NATCO will join Bidvest, which holds the remaining 64.25%, as one of the two key stakeholders in Adcock Ingram.

Adcock Ingram, founded back in 1890, operates across four main verticals—Prescription, OTC, Consumer, and Hospital products. In the financial year ending June 2024, it posted revenue of ZAR 9.6 billion (about USD 536 million), with a healthy EBITDA margin of 14.6% and net profit of ZAR 814 million (USD 45 million).

This deal is part of NATCO’s broader push to expand its global footprint. The company has also decided to set up a new wholly owned subsidiary in South Africa—NATCO Pharma South Africa Proprietary Limited—with an investment cap of ₹2,100 crore. The new entity will act as a holding and operational base to manage its local investments and business in the region.

At the same time, NATCO plans to simplify its overseas structure by liquidating Time Cap Overseas Limited, a current wholly owned subsidiary. Post-liquidation, its Brazilian arm, NatcoFarma do Brasil Ltda., will come under direct ownership of NATCO Pharma.

This acquisition is expected to unlock long-term value for both companies. For Adcock, it brings in NATCO’s strength in R&D, dossier filing, IP access, and reach into regulated markets. NATCO, on the other hand, gets a foothold in a growing market and a chance to synergize operations with a respected local player.

The transaction is likely to close by December 2025, subject to approvals from regulators in India and South Africa. If all goes as planned, Adcock Ingram may also be delisted from the Johannesburg Stock Exchange (JSE).

Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection

Aman Shukla — Mon, 16 Jun 2025 04:03:49 +0000

Natco Pharma shares fell 2% in early trade after the company announced that the U.S. Food and Drug Administration (US FDA) concluded a routine inspection at its API (Active Pharmaceutical Ingredients) facility in Mekaguda, Hyderabad, with one observation. As of 9:32 AM, the shares were trading 2.59% lower at Rs 889.10.

The inspection was carried out over five days, from June 9 to June 13, 2025. In an exchange filing, Natco stated that it received a single Form 483 observation, which it described as procedural in nature. The company expressed confidence in addressing the issue promptly and thoroughly.

“The observation is procedural in nature, and the company is confident of addressing it comprehensively,” Natco said in a statement, reaffirming its commitment to maintaining high compliance standards.

The Mekaguda facility plays a key role in Natco’s API production for global markets. The company reiterated its focus on adhering to current Good Manufacturing Practices (cGMP) and continuing the supply of high-quality pharmaceutical products.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Top stocks to watch today, June 16: NTPC, Godrej Properties, ONGC, Oil India, SpiceJet, Natco Pharma and more

Aman Shukla — Mon, 16 Jun 2025 02:53:23 +0000

Indian stock markets are likely to open on a cautious note on Monday, June 16, as global investors monitor geopolitical tensions in the Middle East. Here’s a look at key stocks that will be in focus today:

ONGC, Oil India, Paint Companies, OMCs

Crude oil prices remain elevated with Brent trading near $75 per barrel due to the ongoing Iran-Israel conflict. This could impact oil-linked sectors including oil exploration companies, paint manufacturers, and oil marketing companies (OMCs).

Vedanta Ltd

The company’s board will meet on June 18 to consider the first interim dividend for FY26. Investors will watch for the dividend quantum and commentary on future payouts.

NTPC

NTPC has commenced operations at one 660 MW phase of its three-phase super thermal power project. The operationalisation adds to the company’s thermal generation capacity.

Godrej Properties

Godrej Properties will develop a 14-acre residential project in Hoskote, East Bengaluru. The project has an estimated revenue potential of ₹1,500 crore.

Syngene International

The US Food and Drug Administration (US FDA) has issued a ‘No Action Indicated’ (NAI) classification for Syngene’s Semicon Park facility in Bengaluru, indicating compliance with regulatory norms.

HBL Power Systems

HBL Engineering has received a Letter of Acceptance (LoA) worth ₹164 crore for Kavach-related work in the Vijayawada–Ballarshah section of South Central Railway.

Zee Entertainment

Zee Entertainment’s board is scheduled to meet today to discuss potential fundraising plans and a long-term growth roadmap over the next three to five years.

Tanla Platforms

The company’s board will meet today to consider a share buyback proposal, which may impact stock movement based on the buyback size and premium.

Birla Corporation

Birla Corp has been declared the preferred bidder for a limestone block spanning 500 hectares in Rajasthan. This could aid raw material security for its cement business.

SpiceJet

The airline reported a net profit in FY25, marking its first annual profit in seven years. EBITDA rose 19% year-on-year. The financial performance may lift investor sentiment.

Sun Pharmaceutical

Sun Pharma has received eight observations from the US FDA for its Halol facility, following an inspection. Regulatory compliance remains a key monitorable.

Nazara Technologies

Investor Rekha Jhunjhunwala has exited Nazara Tech by selling 27.23 lakh shares via block deals on Friday. Stock may react to the large stake sale.

Natco Pharma

The US FDA issued one observation for Natco’s API manufacturing facility in Hyderabad following an inspection.

NATCO Pharma receives one observation after US FDA inspection at Mekaguda API facility

Aman Shukla — Fri, 13 Jun 2025 10:47:17 +0000

NATCO Pharma Limited has announced the successful conclusion of a routine inspection by the U.S. Food and Drug Administration (US FDA) at its Active Pharmaceutical Ingredients (API) manufacturing facility in Mekaguda, Hyderabad.

The inspection was conducted over a five-day period from June 9 to June 13, 2025. Upon conclusion, NATCO received only one observation in the Form 483 issued by the US FDA. According to the company, the observation is procedural in nature, and it is confident in addressing it comprehensively and in a timely manner.

In the excahgne filings, the company shared, “The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from June 9th – June 13th, 2025. On conclusion of the inspection, the Company received 1 (One) observation in the Form-483. The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively.”

NATCO emphasized its ongoing commitment to current Good Manufacturing Practices (cGMP) and assured stakeholders of its continued focus on producing high-quality pharmaceutical products for global markets.

Natco Pharma shares jump 4% as Q4 revenue jumps 14.3% YoY to Rs 1,221 crore

Aman Shukla — Thu, 29 May 2025 04:03:00 +0000

Shares of Natco Pharma jumped 4% in early morning trade following the release of its Q4 results. As of 9:30 AM, the shares were trading 2.64% higher at Rs 885.10.

The pharmaceutical major reported a consolidated net profit of ₹406 crore for the quarter ended March 31, 2025, reflecting a 5% increase compared to ₹386.3 crore in the same period last year. The revenue climbed 16% year-on-year to ₹1,287.3 crore from ₹1,110.3 crore in Q4 FY24.

The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) stood at ₹548 crore, marking a 10.2% increase over the previous year. Despite this improvement, operating margins slightly compressed to 44.89% in the March quarter, down from 46.55% in the corresponding period last year.

Natco Pharma also achieved its highest-ever revenue and net profit for the full financial year 2024–25. The company reported a 16% rise in annual revenue to ₹4,784 crore, while net profit saw a substantial 36% surge to ₹1,883.4 crore.

Natco Pharma shares opened at ₹879.55, reaching a high of ₹919.50 and a low of ₹875.10 during the trading session. The stock is currently trading well below its 52-week high of ₹1,639.00, while remaining above the 52-week low of ₹726.80.

NATCO Pharma plans to launch generic Risdiplam in India, awaiting court clearance

Aman Shukla — Tue, 08 Apr 2025 05:37:20 +0000

NATCO Pharma Limited has issued an update regarding the anticipated launch of its generic version of Risdiplam in India. The company has received significant interest from investors and patients concerning the availability, pricing, and legal status of the drug.

As per the latest legal developments, the Delhi High Court’s Single Judge had earlier, on March 24, 2025, rejected Roche’s plea to block NATCO from launching the drug. However, Roche has appealed this decision. The Appellate Bench has currently directed both parties to maintain the status quo, and the matter remains sub judice.

Due to the ongoing legal proceedings, NATCO has refrained from commenting further on the case. The company reiterated its commitment to launching Risdiplam only after obtaining a favorable and clear directive from the Appellate Bench, which is expected soon.

In line with its stance presented before the court, NATCO has announced the Maximum Retail Price (MRP) of its generic Risdiplam at ₹15,900. Additionally, the company plans to support accessibility by offering discounts through a dedicated patient access program, aiming to assist deserving patients in need.

Natco Pharma shares drop 30% in 2 days following poor Q3 results

Aman Shukla — Fri, 14 Feb 2025 04:10:06 +0000

Shares of Natco Pharma have witnessed a sharp 30% decline in just two days following the release of its weak Q3 FY25 earnings. Today, As of 9:37 AM, the shares were trading 8.85% lower at Rs 888.80.

The pharmaceutical company’s consolidated net profit fell to ₹133 crore in the quarter ending December 31, 2024, a steep drop from ₹212.7 crore in the same period last year.

The revenue also took a significant hit, declining by 37.4% to ₹474.8 crore from ₹758.6 crore in Q3 FY24. Additionally, EBITDA plummeted 86% to ₹38.79 crore, compared to ₹268.1 crore in the year-ago quarter, reflecting a sharp decline in operational performance. Margins narrowed drastically to 8.2% in Q3 FY25, down from 35.3% in the previous year.

Natco Pharma’s shares opened today at ₹950.00, hitting a high of ₹950.00 and a low of ₹875.20. The stock remains volatile, nearing its 52-week low of ₹848.05, significantly down from its 52-week high of ₹1,639.00.

Natco Pharma shares drop 16% as Q3 revenue falls 37% YoY

Aman Shukla — Thu, 13 Feb 2025 03:53:11 +0000

Natco Pharma Ltd. witnessed a sharp decline of 16% in its stock price following a disappointing performance in the third quarter of FY25. The pharmaceutical company’s consolidated net profit fell to Rs 133 crore in the quarter ending December 31, 2024, marking a steep decline from Rs 212.70 crore in the same period last year, as per an exchange filing on Wednesday.

The company’s revenue dropped by 37.4% to Rs 474.80 crore, down from Rs 758.60 crore recorded in Q3 FY24. Additionally, its earnings before interest, tax, depreciation, and amortization (EBITDA) plummeted 86% to Rs 38.79 crore, compared to Rs 268.10 crore in the year-ago quarter.

Margins also took a severe hit, narrowing to 8.2% in the October-December 2024 quarter, significantly lower than 35.3% reported in Q3 FY24. The poor financial results triggered a heavy sell-off, pushing Natco Pharma shares down 16% in intraday trading.

Natco Pharma’s stock opened at ₹1,039.10, reaching a high of ₹1,051.25 and a low of ₹992.15. The stock remains volatile, trading below its 52-week high of ₹1,639.00 but above its 52-week low of ₹829.60.

Natco Pharma Q3 FY25 Results: Revenue down 37.4% to Rs 475 crore, Net Profit declines 37.8% YoY

Aditya Bhagchandani — Wed, 12 Feb 2025 11:04:07 +0000

Natco Pharma Ltd. has reported a significant decline in its financial performance for Q3 FY25, with a sharp drop in revenue, net profit, and EBITDA margins.

Key Financial Highlights (Q3 FY25 vs Q3 FY24):

Revenue: ₹475 crore (▼37.4% YoY from ₹759 crore)
Net Profit (PAT): ₹132.4 crore (▼37.8% YoY from ₹212.7 crore)
EBITDA: ₹38.8 crore (▼85.5% YoY from ₹268.1 crore)
EBITDA Margin: 8.2% (▼2717 bps YoY from 35.3%)

Performance Overview:

The sharp decline in revenue and profit was driven by weaker operational performance and increased expenses. The steep drop in EBITDA margin reflects cost pressures and reduced efficiency in operations.

Market Reaction & Outlook:

The stock reacted negatively to the earnings report, with investors expressing concerns over declining margins.
Natco Pharma’s focus on expanding its specialty pharma business and niche products will be key to reviving growth in the upcoming quarters.

Disclaimer:

The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets

Aman Shukla — Mon, 10 Feb 2025 07:05:34 +0000

Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32 mg. This approval allows the companies to market a generic equivalent of Tracleer® Tablets for Oral Suspension by Actelion Pharmaceuticals US, Inc.

As the exclusive first-to-file applicant, Natco holds a 180-day market exclusivity, providing a competitive edge in the U.S. pharmaceutical market.

Bosentan Tablets for Oral Suspension are used to treat pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH. The medication helps improve pulmonary vascular resistance (PVR), leading to enhanced exercise ability in affected children.

According to IQVIA MAT December 2024, the reference drug Tracleer® generated an estimated USD 11 million in annual U.S. sales. The introduction of this generic version is expected to offer affordable treatment options for pediatric PAH patients while strengthening Lupin and Natco’s presence in the U.S. market.

In the meantime, Lupin’s stock opened today at ₹2,201.90, reaching a high of ₹2,218.80 and a low of ₹2,151.50. The stock remains strong, trading near its 52-week high of ₹2,402.90, significantly above the 52-week low of ₹1,493.30. On the other hand, Natco Pharma’s stock opened at ₹1,314.05, reaching a high of ₹1,321.05 and a low of ₹1,287.05. The stock has seen a 52-week high of ₹1,639.00 and a low of ₹828.00.

Natco Pharma shares rise after selling Telangana land for Rs 115.6 crore

Aditya Bhagchandani — Thu, 28 Nov 2024 04:14:01 +0000

Shares of Natco Pharma edged up 1.01% to ₹1,364.90 in early trading today, following the company’s announcement of selling a 14.38-acre land parcel in Telangana for ₹115.57 crore. The transaction includes infrastructure costs and was finalized on November 27, 2024.

The sold property, located at Mekaguda Gram Panchayat in Ranga Reddy District, Telangana, spans 72,358 square yards. Natco Pharma clarified that the land was not being used for any business operations and that the sale will not impact its core activities.

Known for its innovative pharmaceutical research, Natco Pharma operates eight advanced manufacturing facilities across India. The land sale highlights the company’s strategic monetization of non-operational assets, further strengthening its financial position.

This development reflects positive sentiment among investors as the company continues to focus on its core operational strengths.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.

Natco Pharma sells Telangana land for ₹115.57 crore

Markets Desk — Wed, 27 Nov 2024 12:26:02 +0000

Natco Pharma Limited has announced the sale of a 14.38-acre land parcel, equivalent to 72,358 square yards, located at Mekaguda Gram Panchayat, Nandigama Mandal, Ranga Reddy District, Telangana. The transaction, finalized on November 27, 2024, fetched the company a total consideration of ₹115.57 crore, inclusive of infrastructure costs.

The company clarified that the sold property was not involved in any of its business operations and the transaction will not impact its core activities. The land sale does not qualify as a significant undertaking under Section 180(1)(a) of the Companies Act, 2013.

Natco Pharma emphasized that the buyer is not part of the promoter or promoter group, and the transaction does not fall under related party dealings. Details of the buyer remain confidential as per the agreement. The announcement aligns with Natco Pharma’s strategic initiatives to optimize its asset portfolio.

Natco Pharma submits ANDA for Risdiplam for oral solution

Aman Shukla — Thu, 21 Nov 2024 09:15:49 +0000

Natco Pharma has announced its submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to the U.S. FDA for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL Oral Solution. EVRYSDI, developed by Genentech Inc., is a widely used treatment.

NATCO believes it is among the first two companies to file a substantially complete ANDA for this product. This positions the company to potentially gain 180 days of shared marketing exclusivity upon the generic product’s launch, subject to regulatory approvals and legal proceedings.

The company has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc.

Natco Pharma Q2 FY25 results: Stock surge over 2% ahead of result announcement

Aman Shukla — Tue, 12 Nov 2024 05:24:33 +0000

Shares of Natco Pharma saw a notable rise of over 2%, reaching an intraday high of ₹1,435.40, as investors eagerly anticipate the company’s upcoming Q2 FY25 results.

The stock opened at ₹1,402.00 and has been fluctuating within a tight range, with a 52-week high of ₹1,639.00 and a low of ₹752.45. The positive momentum is driven by market expectations of strong performance, further bolstering investor confidence in the pharmaceutical company’s prospects.

As of 10:55 am, Natco Pharma shares were trading 2.13% higher at Rs 1,425.00 on the NSE.

NATCO Pharma shares surge 3% after announcing settlement in U.S. patent litigation

Aman Shukla — Mon, 07 Oct 2024 03:58:51 +0000

NATCO Pharma shares jumped more than 3% in morning trade after the company announced that Mylan Pharmaceuticals Inc. and Novo Nordisk had settled a U.S. patent litigation concerning developing a generic version of Ozempic (Semaglutide).

The settlement details will remain confidential. NATCO Pharma and Mylan are working together to develop a generic version of Ozempic, a popular treatment for Type 2 diabetes.

As of 9:25 am, NATCO Pharma shares were trading 3.61% higher at Rs 1,402.80 on the NSE.

NATCO Pharma announces settlement in U.S. patent litigation for generic Ozempic

Aditya Bhagchandani — Mon, 07 Oct 2024 03:20:32 +0000

NATCO Pharma Limited has announced that Mylan Pharmaceuticals Inc. and Novo Nordisk have settled a U.S. patent litigation concerning the development of a generic version of Ozempic (Semaglutide). The settlement terms remain confidential. NATCO Pharma and Mylan are jointly developing the generic version of Ozempic, which is widely used for treating Type 2 diabetes.

NATCO’s manufacturing partner for the development of this generic product is Stelis. This settlement marks a key regulatory update for NATCO and its partners as they progress in their collaboration to bring a generic version of Ozempic to the market.

Further details of the settlement and development plans have not been disclosed, in line with the confidentiality agreement between the involved parties.

Natco Pharma stock surges over 4% after submitting FDA application for lung cancer treatment

News Desk — Fri, 30 Aug 2024 04:32:38 +0000

Natco Pharma (NATCOPHARM) shares surged by 4.19%, trading at ₹1,562.00 at 9:59 AM, following the company’s announcement of submitting a product application to the U.S. Food and Drug Administration (FDA) for a generic medication indicated for the treatment of metastatic non-small cell lung cancer.

The application represents a significant step for Natco Pharma as it aims to expand its portfolio in the oncology segment, which has seen increasing demand due to the rising prevalence of cancer. Investors responded positively to the news, reflecting confidence in the company’s growth prospects in the competitive pharmaceutical market.

Natco Pharma Stock Performance Today:

– **Current Price**: ₹1,562.00
– **Change**: ₹62.85 (4.19%)

This surge in stock price indicates market optimism regarding the potential approval of the generic product, which could enhance Natco’s revenue streams. Analysts believe that successful entry into the oncology market could position Natco Pharma favorably against its competitors.

As the company awaits feedback from the FDA, stakeholders will be closely monitoring further developments related to this application, which could significantly impact Natco Pharma’s future performance and market position.

Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug

News Desk — Thu, 29 Aug 2024 09:39:19 +0000

Natco Pharma Limited has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Tabrecta (Capmatinib hydrochloride). The application includes a paragraph IV certification.

Tabrecta, a brand owned by Novartis, is used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) who have a specific type of mutation. The drug recorded sales of $126 million in the U.S. market in 2023.

Natco Pharma believes it is the first company to file a substantially complete ANDA with a paragraph IV certification for this product. If approved, the company may be eligible for 180 days of sole marketing exclusivity for the generic version under certain circumstances.

The generic version will be available in two strengths: 150mg and 200mg base tablets, equivalent to the brand-name product.

This filing is part of Natco Pharma’s ongoing efforts to expand its generic drug portfolio in the U.S. market. The company has disclosed this information in compliance with SEBI regulations.

Natco Pharma shares surge 5% after strong Q4 results

Aditya Bhagchandani — Tue, 28 May 2024 04:44:21 +0000

Natco Pharma shares rose almost 5% in morning trade following the announcement of its Q4 results. The share price opened at ₹1108.95 on the BSE, significantly higher than the previous close of ₹1029.20. On the NSE, the share price touched highs of ₹1100, nearing its 52-week high.

Natco Pharma reported a net profit of ₹386.3 crore for the January to March 2024 quarter, a 40% increase from ₹276 crore in the same period last year. This also marked an 81% rise from the ₹212.7 crore profit reported in the December 2023 quarter. The improvement was driven by strong operating performance, with EBITDA growing 46% to ₹491 crore from ₹336 crore a year ago.

Revenue for the quarter increased by 19% year-on-year to ₹1068.3 crore, up from ₹898 crore in the previous year. With today’s gains, Natco Pharma shares have climbed almost 70% in the past year, providing substantial returns for investors.

As of 10:12 am the shares were trading 3.21% higher at ₹1,062.40 on NSE.

Stocks to watch: Tata Motors, HDFC, Vodafone Idea, TVS, HDFC and more

Aryan Jakhar — Tue, 06 Dec 2022 03:45:10 +0000

The Nifty futures contract on the Singapore Exchange fell 76.5 points, or 0.41 percent, to close at 18,733.5, indicating that Dalal Street will begin Tuesday with a loss.

Tata Motors: The domestic auto giant plans to raise passenger vehicle pricing starting in the next month in order to bring its model range into compliance with the harsher pollution standards that go into effect on April 1 of next year. Additionally, the price adjustment would lessen the effects of commodity prices, which have been high for the majority of the year.

Vodafone-Idea: American Tower Corporation (ATC), a mobile tower firm, raised doubt about Vodafone Idea’s intention to pay its debts in full by the end of January. The debt-ridden Vodafone Idea’s shareholders approved issuing shares worth Rs 1,600 crore to ATC Telecom Infrastructure, the American company’s Indian subsidiary, last month.

HDFC: On 2 December, the Life Insurance Corporation of India (LIC) purchased an additional 2.14 lakh shares, or 0.012%, of the firm. As a result, LIC’s ownership of the Corporation rose from 4.991% to 5.003%.

TVS Motor Company: Promoter Srinivasan Trust sold a stake in TVS Motor Company worth Rs 262 crore. Promoter Srinivasan Trust sold all of its shares in open market transactions for a total of Rs 262.1 crore. At an average price of Rs 1,020 per share, it sold 25.69 lakh shares.

Bajaj Consumer Care: On December 9, the organisation would think about share buybacks. On December 9, the company’s board of directors will review a proposal for the buyback of equity shares.

IRB Infrastructure Developers: The business and its InvIT subsidiary IRB Infrastructure Trust reported a 39% increase in toll revenue collected in November 2022 compared to the same month the previous year for all projects. According to the company, toll revenue in November was Rs 365.95 crore as opposed to Rs 262.81 crore in November 2021.

BCL Industries: BCL Industries receives orders for the delivery of ethanol from OMCs and Reliance Industries. The company has a Rs 285 crore order for 4.9 crore litres of ethanol to be supplied to oil marketing firms. Additionally, its distillery plant received a Rs 107 crore agreement to provide Reliance Industries with 1.65 crore litres of ethanol.

Rainbow Children’s Medicare: British International Investment Plc, a UK company, has left Rainbow Children’s Medicare. The entire investment in Rainbow Children’s Medicare was sold by British International Investment Plc of the UK in open market transactions. British International Investment Plc-owned CDC India Opportunities offloaded 96.32 lakh shares at an average price of Rs. 735.55 per share and CDC Group PLC-owned CDC India Opportunities sold 50.33 lakh shares at an average price of Rs. 735 each, for a combined total of Rs. 1,078.48 crore.

Natco Pharma: In the chlorantraniliprole lawsuit, the business has secured a positive ruling. The Natco Chlorantraniliprole (CTPR) technique does not violate FMC’s Indian Patent No. 298645, according to the Delhi High Court, which dismissed an appeal brought by FMC Corporation, FMC Singapore, and FMC India.

DreamFolks Services: The leading airport service aggregator, DreamFolks Services, and Vidsur Golf have formed a strategic collaboration to give clients access to golf courses around Asia and Europe.

Go Fashion India: Sequoia Capital India sells shares of the company for Rs 228 crore. Canara Robeco Mutual Fund account Canara Robeco Small Cap Fund purchased 3.2 lakh shares of the business through open market transactions for a total of Rs 36.48 crore at an average price of Rs 1,140 per share. However, Sequoia Capital India Investments IV sold 20 lakh shares for a total of Rs 228.02 crore at an average price of Rs 1,140.14 per share.

Stocks to watch today: Adani Enterprises, Nestle India, ONGC, Reliance Industries and others

Aryan Jakhar — Tue, 20 Sep 2022 03:23:00 +0000

As investors wait for the Federal Reserve to announce its interest rate decision sometime this week, the market recovered on September 19 with a 5% gain after losing 3% over the previous three trading sessions. The BSE Sensex increased by 300 points to 59,141, and the Nifty50 increased by 92 points to 17,622.

Here are the top 10 stocks that will be today’s focus are as follows:

Adani Enterprises: On Monday, the flagship firm of the Adani Group, Adani Enterprises, raised Rs 100 crore through the private offering of non-convertible debentures. Positive optimism was there today, and shares of Adani Enterprises increased by almost 3%. The aforementioned MLD will be listed on the BSE’s Wholesale Debt Market. The face value of each of the debentures is Rs. 10 lakh. 1,000 Rated, Listed, Secured, Redeemable, Principal Protected Market Linked Non-Convertible Debentures (MLD) were distributed by the corporation. The face value of each of the debentures is Rs. 10 lakh.

DishTV: Yes Bank Ltd. has increased the stakes in its more than a year-long legal battle with Subhash Chandra-owned Dish TV India Ltd. by asking the Bombay High Court to order the satellite TV operator to host a special shareholder meeting. A division bench of the high court accepted the appeal submitted by Yes Bank, the largest shareholder in Dish TV with a 24.78% stake, on Monday. On Tuesday, the court will consider the petition asking whether Dish TV ought to hold an emergency general meeting (EGM).

Nestle India: According to at least three persons with knowledge of the negotiations, Nestle India Ltd., the regional arm of the largest food corporation in the world, is in talks to acquire a sizeable share in the nutritional snack startup Yoga Bar. One of the three added, on condition of anonymity, “Nestle India has done its due diligence and further conversations are on.”

ONGC: The windfall profit tax on domestically produced crude oil, which has been in place for two and a half months, has ONGC’s attention because the oil ministry claims it violates the contract provisions for fiscal stability. According to the letter, the ministry believed that because incremental profits are transmitted in the form of a bigger profit share for the government, the contracts contain an internal system that takes high pricing into account.

Olectra Greentech: The Thane Municipal Transport Undertaking has issued a Letter of Award to the Olectra Greentech Limited and Evey Trans Private Limited (EVEY) consortia for the supply of 123 electric buses, according to a statement from Olectra on Monday. For a duration of 15 years, these buses will be provided under a Gross Cost Contract (GCC) / OPEX arrangement. According to a statement from Olectra, the deal is worth 185 crore.

Reliance Industries: Fair-trade regulator Reliance Industries The proposed merger of Jio Cinema OTT and Viacom18 Media was approved by the Competition Commission of India (CCI) on Monday. Reliance Industries Ltd. (RIL) and Viacom18 announced a strategic partnership with Bodhi Tree Systems in April. As part of the tripartite partnership, Bodhi Tree will invest 13,500 crore in Viacom18, and Reliance Projects & Property Management Services, a wholly-owned subsidiary of RIL, will invest 1,645 crore in the broadcaster, creating one of the largest TV and digital streaming firms in India.

Ircon International: According to sources, Mahanadi Coalfields has given Ircon International a work order for 256 crore for Ananta OCP of Jagannath Area in Talcher. For the development of rail infrastructure, the work order is for thorough engineering and project management consulting services.

Natco Pharma: On Monday, Natco Pharma announced that it had been granted permission by a judge to introduce the insecticide Chlorantraniliprole (CTPR) and its formulations. The Delhi High Court has given the business permission to introduce the insecticide using a non-infringing procedure, the Hyderabad-based company reported in a regulatory filing. A patent infringement lawsuit against Natco Pharma was brought in the Delhi High Court by the US-based FMC Corporation.

Future Supply Chains: On Monday, Future Supply Chains Ltd (FSCL) announced that it had abandoned efforts to sell firm assets due to the anticipated delay in acquiring other necessary clearances. According to FSCL’s regulatory filing, its board has decided to “rescind the plan to proceed with sale/disposal of the Business Undertaking” due to a “anticipated delay in collecting other necessary clearances.”

Ashok Leyland: At a time when commercial vehicle manufacturers are getting ready to invest in electric vehicles, natural gas, and flexible fuel platforms, Ashok Leyland Ltd anticipates that hydrogen-powered trucks and buses will emerge as a self-sufficient green solution with commercial viability starting in the next five years. According to N. Saravanan, chief technology officer of the Hinduja Group company, hydrogen-powered long-haul trucks could reduce total cost of ownership (TCO) compared to compressed natural gas (CNG) variations at the correct level of acceptance and affordability.